[en] INTRODUCTION: Metabolic Associated Fatty Liver Disease (MAFLD) is currently the main cause of chronic liver disease. To avoid its progression, it's required the coordination between Primary Care (PC) and specialized care, in order to know the profile of the patient with MAFLD who is referred from PC to specialized care through electronic interconsultation (eIC) as well as its management. METHODS: We analysed the eIC carried out between January/2018 and December/2020 from PC to specialized care. Once eIC related to MAFLD were identified, we recorded demographic, laboratory, and clinical variables and the attitude of the specialist. Liver fibrosis was estimated from the FIB-4 index. RESULTS: We registered a total of 10969 eIC, identifying 385 (3.5%) due to MAFLD (53.8% men, 54.3±13.5 years). Of these, 11.2% were due to hypertransaminasemia, 53.2% due to ultrasound findings and hypertransaminasemia, and 35.6% due only to ultrasound findings. 34.3% had type II diabetes, 55.1% hypertension, 68.6% dyslipidaemia, 54.8% obesity, and 48.6% metabolic syndrome. Among the diabetic patients (n=132), 67.4% were being treated with metformin and 5.3% with glucagon-like peptide-1 (GLP-1). 55.6% of patients were teetotallers. 38,8% (n=148) had a high risk of suffering ≥F2. Among these, 27% were discharged without follow-up (35% with no recommendations at discharge). CONCLUSION: There is a low referral percentage of patients with MAFLD from PC, a third of them having a high risk of suffering from advanced fibrosis. This patient profile represents an opportunity for early detection and treatment of MAFLD, being necessary to implement protocols and care circuits coordinated with PC.

[es] INTRODUCCIÓN: La esteatosis hepática metabólica (EHmet) supone actualmente la principal causa de hepatopatía crónica. Evitar su progresión requ iere la coordinación entre Atención Primaria (AP) y especializada siendo preciso conocer el perfil de paciente con EHmet que es derivado desde AP a especializada a través de la interconsulta electrónica (ICe) y el manejo desde especializada. MÉTODOS: Analizam os las ICe realizadas entre enero/2018 y diciembre/2020 desde AP a especializada. Identificadas las relacionadas con EHmet, se registraron variables demográficas, de laboratorio, clínicas y actitud por parte del especialista. Se estimó la fibrosis hepática a partir del índice FIB RESULTADOS:4. Registramos un total de 10969 ICe, identificando 385 (3,5%) por EHmet (53,8% hombres, 54,3±13,5 años). De estas, un 11,2% fue por hipertransaminasemia, 53,2% por hallazgos ecográficos e hipertransaminasemia, y en u n 35,6% sólo por hallazgos ecográficos. El 34,3% tenían diabetes tipo II, 55,1% hipertensión, 68,6% dislipemia, 54,8% obesidad, y 48,6% síndrome metabólico. De los pacientes diabéticos (n=132), el 67,4% tomaba metformina y el 5,3% un análogo humano del pép tido1 similar al glucagón (GLP1). El 55,6% eran abstemios. 38,8% (n=148) presentaban riesgo alto de padecer ≥F2. De estos, el 27% fue dado de alta sin seguimiento (35% sin recomendaciones al alta). CONCLUSIÓN: Existe un bajo porcentaje de derivación de p acientes con EHmet desde AP, teniendo una tercera parte riesgo alto de padecer fibrosis avanzada. Este perfil de paciente supone una oportunidad de detección precoz y tratamiento de EHmet, por lo que urge implementar protocolos y circuitos asistenciales co nsensuados con AP.